Liver Transplant for Nonhepatocellular Carcinoma Malignancy

dc.contributor.authorReyhan, Nihan Haberal
dc.contributor.orcID0000-0001-9852-9911en_US
dc.contributor.pubmedID28302003en_US
dc.contributor.researcherIDAAK-4587-2021en_US
dc.date.accessioned2023-08-03T08:52:28Z
dc.date.available2023-08-03T08:52:28Z
dc.date.issued2017
dc.description.abstractLiver transplant is now an acceptable and effective treatment for specific nonhepatocellular malignancies. Worldwide, hilar cholangiocarcinoma accounts for 3% of all primary gastrointestinal malignancies and for 10% of primary hepatobiliary malignancies. For patients who have early-stage, unresectable cholangiocarcinoma, liver transplant preceded by neoadjuvant radiotherapy can result in tumor-free margins, accomplish a radical resection, and treat the underlying primary sclerosing cholangitis when present. Hepatic epithelioid hemangioendothelioma is a rare tumor of vascular origin with a variable malignant potential. Excellent results have been reported with liver transplant for patients with unresectable hepatic epithelioid hemangioendo thelioma, with 1-year and 10-year survival rates of 96% and 72%. Hepatoblastoma is the most common primary hepatic malignancy in children. The long-term survival rate after transplant ranges from 66% to 77% in patients with unresectable tumors and good response to chemotherapy. Metastatic liver disease is not an indication for liver transplant, with the exception of cases in which the primary tumor is a neuroendocrine tumor. Indication for liver transplant for hepatic metastasis from neuroendocrine tumors is mainly for patients with unresectable tumors and for palliation of medically uncontrollable symptoms. Posttransplant survival in those patients with low tumor activity index is excellent, despite recurrence of the tumor. Some recent data on liver transplant for unresectable hepatic metastases from colorectal cancer have reported limited survival benefits compared with previous reports. However, due to the high rate of tumor recurrence in a very short time after liver transplant, especially in the era of organ shortage, this indication has not been favored by the transplant community. The indications for liver transplant for nonhepatocellular carcinoma malignancy and its limitations have evolved dramatically over the past decades and will continue to be redefined through future research and investigations.en_US
dc.identifier.endpage73en_US
dc.identifier.issn1304-0855en_US
dc.identifier.issueSupplement 2en_US
dc.identifier.scopus2-s2.0-85016423032en_US
dc.identifier.startpage69en_US
dc.identifier.urihttp://hdl.handle.net/11727/10102
dc.identifier.volume15en_US
dc.identifier.wos000399334300014en_US
dc.language.isoengen_US
dc.relation.isversionof10.6002/ect.TOND16.L18en_US
dc.relation.journalEXPERIMENTAL AND CLINICAL TRANSPLANTATIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCholangiocarcinomaen_US
dc.subjectHepatic epithelioid hemangioendotheliomaen_US
dc.subjectHepatoblastomaen_US
dc.subjectMetastatic liver diseaseen_US
dc.titleLiver Transplant for Nonhepatocellular Carcinoma Malignancyen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: